26 February 2016 - Gilead Sciences, Inc. today announced that the CHMP, the scientific committee of the EMA, has adopted a positive opinion on the company’s marketing authorization application for two doses of Descovy (emtricitabine and tenofovir alafenamide), an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents (ages 12 years and older with body weight at least 35 kg) in combination with other HIV anti-retroviral agents.

For more details, go to: http://www.gilead.com/news/press-releases/2016/2/european-chmp-adopts-positive-opinion-for-gileads-fixeddose-combination-descovy-emtricitabinetenofovir-alafenamide-for-the-treatment-of-hiv